Get the Stockscreener App
0.2025
16.00%
-0.0375
Virpax Pharmaceuticals Inc stock is traded at $0.2025, with a volume of 5.53M.
It is down -16.00% in the last 24 hours and down -30.72% over the past month.
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
See More
Previous Close:
$0.24
Open:
$0.2033
24h Volume:
5.53M
Relative Volume:
0.76
Market Cap:
$3.67M
Revenue:
-
Net Income/Loss:
$-13.24M
P/E Ratio:
-0.0229
EPS:
-8.83
Net Cash Flow:
$-16.85M
1W Performance:
-20.00%
1M Performance:
-30.72%
6M Performance:
-75.28%
1Y Performance:
-94.26%
1-Day Range:
$0.19
$0.2097
1-Week Range:
$0.19
$0.29
52-Week Range:
$0.19
$5.48
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Name
Virpax Pharmaceuticals Inc
Sector
Industry
Phone
610-727-4597
Address
1055 WESTLAKES DRIVE, SUITE 300, BERWYN
Compare VRPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.2016 | 3.67M | 0 | -13.24M | -16.85M | -8.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.12 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.15 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
633.23 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.19 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.67 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Virpax Pharmaceuticals Inc Stock (VRPX) Latest News
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Virpax Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:VRPX - Benzinga
Virpax lauds Nanomerics’ MET study with no severe side effects By Investing.com - Investing.com Australia
Virpax Pharmaceuticals reports Molecular Envelope Technology human study data - TipRanks
Virpax lauds Nanomerics’ MET study with no severe side effects - Investing.com India
Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - StockTitan
Virpax(R) Pharmaceuticals to Present at ThinkEquity Conference - ACCESS Newswire
Virpax Pharmaceuticals Advances Pain Management with Promising Probudur Study Results - MSN
Virpax reports positive study results for pain management drug - MSN
Breakthrough in Pain Relief: Virpax Pharmaceuticals Soars with US Army Collaboration - Bit Perfect Solutions
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Benzinga
Virpax reports positive study results for pain management drug By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals confirms results with U.S. Army with Probudur - TipRanks
Military Breakthrough: New Pain Control Drug Shows 96-Hour Combat Effectiveness in Army Tests - StockTitan
Promising Nanotechnology Stocks To Follow TodayFebruary 11th - MarketBeat
Nanotechnology Stocks To Keep An Eye OnFebruary 08th - MarketBeat
Promising Nanotechnology Stocks To Watch TodayFebruary 06th - MarketBeat
Nanotechnology Stocks To Follow NowFebruary 05th - MarketBeat
Promising Nanotechnology Stocks To Watch Today – February 06th - Armenian Reporter
Virpax Pharmaceuticals Inc (VRPX) Stock: What the Analysts are Saying - The News Heater
Virpax Pharmaceuticals Appoints Charn Deol as Independent DirectorVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) announced on February 5, 2025, the appointment of Mr. Charn Deol as an independent director of the Company, effective immediately. Mr. D - Defense World
Virpax Pharmaceuticals appoints new independent director By Investing.com - Investing.com Australia
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax Pharmaceuticals Appoints Charn Deol as Independent Director - TipRanks
Virpax Pharmaceuticals director resigns due to compliance - MSN
Virpax Pharmaceuticals director resigns due to compliance By Investing.com - Investing.com Canada
Virpax Pharmaceuticals Board Member Jay Panis Resigns - TipRanks
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference - MSN
Best Nanotechnology Stocks To Follow TodayJanuary 30th - MarketBeat
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
VRPXVirpax Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Clinical Trials Innovation: Virpax Leadership Takes Center Stage at Elite OCT Conference - StockTitan
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering - GlobeNewswire
Virpax Pharmaceuticals Raises $6M and Signs Investor Agreements - TipRanks
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering - The Manila Times
Virpax Pharmaceuticals Closes of $6.0 Million Public Offering of Common Stock - citybiz
Virpax Secures Critical $6M Funding: What This Means for Probudur's Future - StockTitan
Virpax Pharmaceuticals Prices of $6 Million Public Offering of Common Stock - citybiz
Virpax Pharmaceuticals Announces $6 Mln Public Offering For Pain Relief Innovations - Nasdaq
Virpax Pharmaceuticals Inc Stock (VRPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.34%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):